Richter Gedeon Vegyészeti Gyár Nyrt. has acquired Celmatix’s discovery portfolio focused on women’s health, including a first-in-class oral FSH receptor agonist for fertility care, a JNK inhibitor program for a potential non-hormonal endometriosis immunotherapy, and early-stage therapeutic antibodies targeting anti-Müllerian hormone. Celmatix will receive an upfront payment and is eligible for development milestone payments as the programs advance, with development to be led by Richter’s women’s health R&D hub in Belgium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gedeon Richter plc published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.